Journal
AMERICAN JOURNAL OF HYPERTENSION
Volume 18, Issue 5, Pages 720-730Publisher
OXFORD UNIV PRESS
DOI: 10.1016/j.amjhyper.2004.11.032
Keywords
renin-angiotensin-aldosterone system; angiotensin II receptor blockers; receptors; angiotensin antagonists and inhibitors; antihypertensive agents; pharmacology
Categories
Ask authors/readers for more resources
The renin-angiotensin-aldosterone system (RAAS) regulates sodium balance, fluid volume, and blood pressure (BP). It is also implicated in the progression of heart failure, hypertension, and kidney disease; this is mediated by the binding of angiotensin II (ang II) to the ang II type 1 but not the ang II type 2 receptor. Preclinical and clinical studies have shown that blockade of the RAAS with ang II receptor blockers (ARB) is effective not only in controlling BP but also in preventing end-organ damage. Through their mechanism of action, ARB may offer benefit with respect to endothelial dysfunction and vascular remodeling, as well as cardiac and renal protection. In addition, both recent and ongoing clinical trials help to clarify further the mechanisms for the benefits of using ARB across the cardiovascular continuum. (c) 2005 American Journal of Hypertension, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available